Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

NCT05657301 is registered in ClinicalTrials.gov with Chengdu Origen Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05657301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05657301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
Lead sponsor
Chengdu Origen Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 16, 2023
Completion date
September 30, 2027
Enrollment
25 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration